^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations

Excerpt:
...Confirmed diagnosis of a malignancy harbouring HER2 amplification, or an appropriate activating mutation as defined by the MTB, using an analytically validated method....
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

978P - Pertuzumab plus trastuzumab (P+T) in patients (pts) with lung cancer (LC) with ERBB2 mutation (mut) or amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study

Published date:
09/05/2022
Excerpt:
Combination P+T showed evidence of anti-tumor activity in heavily pre-treated pts with LC and ERBB2 mut or amp.
Trial ID: